Search

[No abstract available], [03-107-13/2013], The study is carried out in accordance with the code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study involves blood from patients with leukemia. The Ankara University, School of Medicine Ethics Committee approved the study protocol (project No. 03-107-13/2013), and informed consent was provided by the patients' parents.

[No abstract available], [03-107-13/2013], The study is carried out in accordance with the code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. This study involves blood from patients with leukemia. The Ankara University, School of Medicine Ethics Committee approved the study protocol (project No. 03-107-13/2013), and informed consent was provided by the patients' parents.

Background/Objectives: BCP‐ALL (B‐cell precursor acute lymphoblastic leukemia) is characterized by recurring cytogenetic and molecular genetic abnormalities. We aimed to investigate recently identified genomic risk factors that affect the pathogenesis of BCP‐ALL, with effects on their molecular mechanism and prognostic significance by Next Generation Sequence (NGS) and gene expression analyses in childhood BCP‐ALL. The secondary aim of this study was to correlate the data obtained from study with some biological and clinical features as characteristic of pediatric BCP‐ALL patients, genetic aberrations and prognosis based on treatment protocol criteria.

Background/Objectives: BCP‐ALL (B‐cell precursor acute lymphoblastic leukemia) is characterized by recurring cytogenetic and molecular genetic abnormalities. We aimed to investigate recently identified genomic risk factors that affect the pathogenesis of BCP‐ALL, with effects on their molecular mechanism and prognostic significance by Next Generation Sequence (NGS) and gene expression analyses in childhood BCP‐ALL. The secondary aim of this study was to correlate the data obtained from study with some biological and clinical features as characteristic of pediatric BCP‐ALL patients, genetic aberrations and prognosis based on treatment protocol criteria.